Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis

James N. George

doi:10.1160/TH08-05-0278

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(06): 987-988
DOI: 10.1160/TH08-05-0278

Editorial Focus

Schattauer GmbH

Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis

Authors

James N. George

¹Colleges of Public Health and Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

Abstract

Full Text

References

References
1 Furlan M, Robles R, Galbusera M. et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New Engl J Med 1998; 339: 1578-1584.
2 Tsai H-M, Lian ECY. Antibodies to von-Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New Engl J Med 1998; 339: 1585-1594.
3 Uemura M, Fujimura Y, Matsumoto M. et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99: 1019-1029.
4 Bianchi V, Robles R, Alberio L. et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-713.
5 Ono T, Mimuro J, Madoiwa S. et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-534.
6 Nguyen TC, Liu A, Liu L. et al. Acquired ADAMTS13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92: 121-124.
7 Uemura M, Tatsumi K, Matsumoto M. et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
8 Banno F, Kokame K, Okuda T. et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006; 107: 3161-3166.
9 Chauhan AK, Walsh MT, Zhu G. et al. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008; 111: 3452-3457.
10 Peyvandi F, Lavoretano S, Palla R. et al. ADAMTS 13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-239.
11 Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139-159.
12 Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine 1981; 60: 413-428.
13 Laszik ZG, Silva FG. Hemolytic uremic syndrome, thrombotic thrombocytopenia purpura, and other thrombotic microangiopathies and coagulopathies. In: Heptinstall’s Pathology of the Kidney. Lippincott Williams & Wilkins; Philadelphia: 2007: 699-762.
14 Matsumoto M, Kokame K, Soejima K. et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004; 103: 1305-1310.
15 George JN. Congenital thrombotic thrombocytopenic purpura: Lessons for recognition and management of rare syndromes. Pediatr Blood Cancer 2008; 50: 947-948.